News & Updates

In the real-world treatment of older adults with inflammatory bowel disease (IBD), the cardiovascular safety of ustekinumab is similar to that of vedolizumab, with no significant difference in the risk of major adverse cardiovascular events (MACE). However, ustekinumab is associated with a reduced risk of all-cause mortality.

Pregnant women with colorectal cancer (CRC) face a considerably increased likelihood of severe maternal morbidity, including disseminated intravascular coagulation, acute respiratory distress syndrome, and hysterectomy, among others, according to a study.

Treatment with colchicine appears to lower the risk of stroke and major adverse cardiovascular events (MACE) when used for longer duration, according to a study presented at ISC 2025. This beneficial effect, however, is not observed among patients with shorter follow-up duration.

The addition of intravenous thrombolysis (IVT) to endovascular thrombectomy (EVT) provides significant clinical benefits to patients who experienced acute ischaemic stroke (AIS) caused by large vessel occlusion (LVO) with large ischaemic infarcts (LII), as shown by the findings of a meta-analysis presented at the recent ISC 2025.